MARCH 29 (Reuters) – Patients who stop using weight-loss drugs such as WeGobee are at risk of regaining their previous weight in about five years, a Novo Nordisk (NOVOb.CO) official said Wednesday. rice field.
Based on individual profiles, patients may return to about half their original weight in 2-3 years if treatment is discontinued.
Comments indicate that weight recovery may be slower than previously known.
Data funded by Novo study Last April, patients were shown to have regained two-thirds of the weight they had lost a year after stopping the drug.
The data pointed to the chronic nature of obesity, suggesting that ongoing treatment is required to maintain weight and health.
Wegovy, a semaglutide-based drug, is approved in the US for the treatment of adult obesity. This drug activates GLP-1, a hormone that causes the body to feel full after eating.
Reported by Mariam Sunny and Bhanvi Satija, Bangalore. Edited by Sriraj Kalluvila
Our criteria: Thomson Reuters Trust Principles.
